Literature DB >> 2418109

Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting.

R S Labib, G J Anhalt, H P Patel, D F Mutasim, L A Diaz.   

Abstract

Sera from 28 patients with bullous pemphigoid (BP), four patients with cicatricial pemphigoid (CP), and 24 controls (normal volunteers and patients with pemphigus, systemic lupus erythematosus, or other skin diseases) were tested against extracts of human epidermis by immunoblotting techniques. The extraction buffer included 1% SDS, 5% beta-mercaptoethanol, and six protease inhibitors with various specificities. BP sera from individual patients showed different patterns of reactivity with the same epidermal extract, and each pattern consisted of one or more bands. A total of five bands of 240 kD, 200 kD, 180 kD, 97 kD, and 77 kD reacted with BP sera; the 240-kD band reacted with one CP sera, and none of these bands was detected by the control sera. The 240-kD and 180-kD bands reacted very strongly with some sera and were most frequently observed (43% and 29%, respectively). The 200-kD, 97-kD, and 77-kD bands were less frequently observed (25%, 7%, and 7%, respectively), but when present, their reactions were usually strong. Eleven percent of the BP sera did not react with any bands. Contrary to previous reports, this study shows that BP autoantibodies react with several protein bands, as detected by immunoblotting. We have recently shown by immunoelectron microscopy that BP autoantibodies bind to the basal cell hemidesmosomes. It remains to be determined which of these protein bands represent specific hemidesmosomal proteins and which antibody-antigen interactions are relevant to the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418109

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  79 in total

1.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  [Mycophenolate mofetil as effective therapy option in scarring pemphigoid].

Authors:  I Elser; D Selimovic; T Ruzicka; A Kuhn; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

3.  Detection of pemphigus vulgaris antigen on COLO and SCaBER tumor cell lines by the immunoblot technique.

Authors:  N M Mirza; A Mohimen; A R Ahmed
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8.

Authors:  Françoise Van den Bergh; Steven L Eliason; Brian T Burmeister; George J Giudice
Journal:  Exp Dermatol       Date:  2012-08       Impact factor: 3.960

Review 5.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.

Authors:  J R Stanley
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332.

Authors:  F Van den Bergh; S L Eliason; G J Giudice
Journal:  Matrix Biol       Date:  2010-10-26       Impact factor: 11.583

7.  [Successful treatment of subcorneal pustular type of IgA pemphigus].

Authors:  U Raap; B Völker; H Petering; T Hashimoto; D Zillikens; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

8.  Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.

Authors:  A Ishiko; H Shimizu; A Kikuchi; T Ebihara; T Hashimoto; T Nishikawa
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Role of methotrexate in the treatment of bullous pemphigoid in the elderly.

Authors:  Timothy Patton; Neil Korman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.